OptiNose Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptiNose in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OptiNose stock.
View analyst ratings for OptiNose or view top-rated stocks.

Wall Street analysts have given OptiNose a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but OptiNose wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

OptiNose saw a increase in short interest during the month of February. As of February 12th, there was short interest totaling 4,720,000 shares, an increase of 33.3% from the January 28th total of 3,540,000 shares. Based on an average daily trading volume, of 477,400 shares, the days-to-cover ratio is currently 9.9 days. Approximately 16.3% of the shares of the stock are sold short.
View OptiNose's Short Interest.

OptiNose is scheduled to release its next quarterly earnings announcement on Wednesday, March 3rd 2021.
View our earnings forecast for OptiNose.

OptiNose will be holding an earnings conference call on Wednesday, March 3rd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

OptiNose, Inc. (NASDAQ:OPTN) announced its quarterly earnings data on Thursday, November, 5th. The company reported ($0.43) EPS for the quarter, topping the Zacks' consensus estimate of ($0.56) by $0.13. The firm earned $15.44 million during the quarter, compared to analysts' expectations of $15.40 million. OptiNose had a negative net margin of 230.14% and a negative trailing twelve-month return on equity of 294.64%.
View OptiNose's earnings history.

OptiNose's stock was trading at $5.06 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, OPTN shares have decreased by 20.6% and is now trading at $4.02.
View which stocks have been most impacted by COVID-19.

3 equities research analysts have issued 12 month target prices for OptiNose's stock. Their forecasts range from $17.00 to $21.00. On average, they anticipate OptiNose's stock price to reach $19.00 in the next year. This suggests a possible upside of 372.6% from the stock's current price.
View analysts' price targets for OptiNose or view top-rated stocks among Wall Street analysts.

Some companies that are related to OptiNose include Kadmon (KDMN), AnaptysBio (ANAB), Esperion Therapeutics (ESPR), Provention Bio (PRVB), Intercept Pharmaceuticals (ICPT), Gossamer Bio (GOSS), Merus (MRUS), OrganiGram (OGI), Rigel Pharmaceuticals (RIGL), Akouos (AKUS), Chinook Therapeutics (KDNY), Emisphere Technologies (EMIS), Calliditas Therapeutics AB (publ) (CALT), Albireo Pharma (ALBO) and Xenon Pharmaceuticals (XENE).
View all of OPTN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other OptiNose investors own include Proteostasis Therapeutics (PTI), Idera Pharmaceuticals (IDRA), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Selecta Biosciences (SELB), VBI Vaccines (VBIV), Strongbridge Biopharma (SBBP) and SCYNEXIS (SCYX).

(OPTN) raised $101 million in an initial public offering (IPO) on Friday, October 13th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO.

OptiNose trades on the NASDAQ under the ticker symbol "OPTN."

OptiNose's stock is owned by many different retail and institutional investors. Top institutional shareholders include Paradigm Capital Management Inc. NY (4.80%), BlackRock Inc. (4.50%), Tamarack Advisers LP (3.79%), Rice Hall James & Associates LLC (1.99%), Opaleye Management Inc. (0.84%) and Northern Trust Corp (0.74%). Company insiders that own OptiNose stock include Avista Capital Partners Ii Gp,, Joseph C Scodari, Keith A Goldan, Michael F Marino III, Peter K Miller, Ramy A Mahmoud and Thomas Edward Gibbs.
View institutional ownership trends for OptiNose.

OPTN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Caas Capital Management LP, Walleye Capital LLC, Squarepoint Ops LLC, Rice Hall James & Associates LLC, Bank of New York Mellon Corp, Barclays PLC, and Alliancebernstein L.P.. Company insiders that have sold OptiNose company stock in the last year include Peter K Miller, and Ramy A Mahmoud.
View insider buying and selling activity for OptiNose or view top insider-selling stocks.

OPTN stock was bought by a variety of institutional investors in the last quarter, including Opaleye Management Inc., Paradigm Capital Management Inc. NY, JPMorgan Chase & Co., Tamarack Advisers LP, Virtu Financial LLC, Renaissance Technologies LLC, ExodusPoint Capital Management LP, and Nuveen Asset Management LLC. Company insiders that have bought OptiNose stock in the last two years include Joseph C Scodari, Keith A Goldan, and Michael F Marino III.
View insider buying and selling activity for OptiNose or or view top insider-buying stocks.

Shares of OPTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OPTN stock can currently be purchased for approximately $4.02.

OptiNose has a market capitalization of $209.37 million and generates $34.63 million in revenue each year. The company earns $-110,050,000.00 in net income (profit) each year or ($2.63) on an earnings per share basis.

OptiNose employs 221 workers across the globe.

The official website for OptiNose is www.optinose.com.

OptiNose is headquartered at 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067.

OptiNose's mailing address is 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067. The company can be reached via phone at 267-364-3500 or via email at [email protected]